ENXTBR:ARGXBiotechs
Assessing Argenx (ENXTBR:ARGX) Valuation After Vyvgart Priority Review And Upbeat Analyst Upgrades
argenx (ENXTBR:ARGX) is back in focus after the FDA accepted priority review for an expanded Vyvgart application, alongside fresh analyst commentary pointing to strong Vyvgart sales momentum and higher long term revenue assumptions.
See our latest analysis for argenx.
At a share price of €717.6, argenx has seen a 4.97% 1 month share price return. Its 1 year total shareholder return of 11.92% and 3 year total shareholder return of 104.04% point to momentum that has built over a longer period,...